Left ventricular remodelling in asymptomatic HIV infection on chronic HAART: Comparison between hypertensive and normotensive subjects with and without HIV infection

Journal of Human Hypertension

Volumn 26, Issue 10, 2012, Pages 570-576

  Grandi, A M ^a   Nicolini, E ^a   Giola, M ^a   Gianni, M ^a   Maresca, A M ^a   Marchesi, C ^a   Guasti, L ^a   Balsamo, M L ^a   Venco, A ^a   Grossi, P A ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

diastolic function; highly active antiretroviral therapy; HIV infection; left ventricular hypertrophy; metabolic syndrome

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD EXAMINATION; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BODY MASS; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE REMODELING; HEART VENTRICLE REMODELING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; SMOKING;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84866426076     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2011.81     Document Type: Article

References (39)

1. Palella F, Delaney K, Moorman A, Palella Jr FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced huMAn immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
2. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008; 118: e29-e35.
3. Grunfeld C, Kotler DP, Arnett DK, Falutz JM, Haffner SM, Hruz P et al. Contribution of metabolic and anthropometric abnorMAlities to cardiovascular disease risks factors. Circulation 2008; 118: e20-e28.
4. Dubé MP, Lipshultz SE, Fichtenbaum CJ, Greenberg R, Schecter AD, Fisher SD et al. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation 2008; 118: e36-e40.
5. Ho JE, Hsue PY. Cardiovascular MAnifestations of HIV infection. Heart 2009; 95: 1193-1202.
6. Jerico C, Knobel H, Montero M, Sorli ML, Guelar A, Gimeno JL et al. Hypertension in HIV-infected patients: prevalence and related factors. Am J Hypertens 2005; 18: 1396-1401.
7. BaekkenM, Os I, Sandvik L, Oektedalen O. Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy. J Hypertens 2008; 26: 2126-2133.
8. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular MAss in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
9. Schillaci G, Pasqualini L, Verdecchia P, Vaudo G, Marchesi S, Porcellati C et al. Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol 2002; 39: 2005-2011.
10. Stein JH, Hadigan CM, Brown TT, Chadwick E, Feinberg J, Friis-Moller N et al. Prevention strategies for cardiovascular disease in HIV-infected patients. Circulation 2008; 118: e54-e60.
11. Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with huMAn immunodeficiency virus. Am J Med 2005; 118(Suppl 2): 23-28.
12. Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular MAss and geometry. The Framingham Heart Study. JAMA 1991; 266: 231-236.
13. Grandi AM, Zanzi P, Fachinetti A, Gaudio G, Ceriani L, Bertolini A et al. Insulin and diastolic dysfunction in lean and obese hypertensives. Genetic influence. Hypertension 1999; 34: 1208-1214.
14. De las Fuentes L, Brown AL, Mathews SJ, Waggoner AD, Soto PF, Gropler RJ et al. Metabolic syndrome is associated with abnorMAl left ventricular diastolic function independent of left ventricular MAss. Eur Heart J 2007; 28: 553-559.
15. Sundstrom J, Arnlov J, Stolare K, Lind L. Blood pressure-independent relations of left ventricular geometry to the metabolic syndrome and insulin resistance: a population-based study. Heart 2008; 94: 874-878.
16. Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C et al. Metabolic syndrome in the Pressione Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac daMAge and prognosis. Hypertension 2007; 49: 40-47.
17. Coudray N, de Zuttere D, Force G, Champetier de Ribes D, Pourny JC et al. Left ventricular diastolic function in asymptoMAtic and symptoMAtic huMAn immunodeficiency virus carriers: an echocardiographic study. Eur Heart J 1995; 16: 61-67.
18. Barbaro G, Barbarini G, Di Lorenzo G. Early impairment of systolic and diastolic function in asymptoMAtic HIV-positive patients: a multicenter echocardiographic and echo-Doppler study. AIDS Res Hum Retrov 1996; 12: 1559-1562.
19. Longo-Mbenza B, Seghers LV, Vita EK, Tonduangu K, Bayekula M. Assessment of ventricular diastolic function in AIDS patients from Congo: a Doppler echocardiographic study. Heart 1998; 80: 184-189.
20. Cardoso JS, Moura B, Martins L, Mota-Miranda A, Rocha Gonçalves F, Lecour H. Left ventricular dysfunction in huMAn immunodeficiency virus (HIV)-infected patients. Int J Cardiol 1998; 63: 37-45.
21. Mart́nez-Garća T, Sobrino JM, Pujol E, Galvez J, Beńtez E, Girón-González JA. Ventricular MAss and diastolic function in patients infected by the huMAn immunodeficiency virus. Heart 2000; 84: 620-624.
22. Umana E, Panayiotou H, Ramsey KA, Bikkina M, massey CV, Alpert MA. Left ventricular MAss and systolic function in huMAn immunodeficiency virusinfected patients after weight loss. Am J Cardiol 2000; 86: 1040-1043, A11.
23. Meng Q, Lima JA, Lai H, Vlahov D, Celentano DD, Strathdee S et al. Use of HIV protease inhibitors is associated with left ventricular morphologic changes and diastolic dysfunction. J Acquir Immune Defic Syndr 2002; 30: 306-310.
24. Mansoor A, Golub ET, Dehovitz J, Anastos K, Kaplan RC, Lazar JM. The association of HIV infection with left ventricular MAss/hypertrophy. AIDS Res Hum Retroviruses 2009; 25: 475-481.
25. Friedewald WT, Levy RI, Fredrickson DS. EstiMAtion of the concentration of low-density lipoprotein cholesterol in plasMA, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasMA glucose and insulin concentrations in MAn. Diabetologia 1985; 28: 412-419.
27. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and MAnagement of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
28. Devereux RB, Reichek N. Echocardiographic determination of left ventricular MAss in MAn. Anatomic validation of the method. Circulation 1977; 55: 613-618.
29. De Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O et al. Left ventricular MAss and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992; 20: 1251-1260.
30. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification. Eur J Echocardiogaphy 2006; 7: 79-108.
31. Grandi AM, Venco A, Barzizza F, Casadei B, Marchesi E, Finardi G. Effect of enalapril on left ventricular MAss and perforMAnce in essential hypertension. Am J Cardiol 1989; 63: 1093-1097.
32. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular MAss by antihypertensive treatment. A meta-analysis of randomized comparative studies. Hypertension 2009; 54: 1084-1091.
33. Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L, Cappuccio FP. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension 2007; 49: 792-798.
34. Ge CJ, Lu SZ, Chen YD, Wu XF, Hu SJ, Ji Y. Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodelling, and C-reactive protein in hypertensive patients with priMAry hypercholesterolemia. Heart Vessels 2008; 23: 91-95.
35. Payne JR, James LE, Eleftheriou KI, Hawe E, Mann J, Stronge A et al. The association of left ventricular MAss with blood pressure, cigarette smoking and alcohol consumption; data from the LARGE Heart study. Int J Cardiol 2007; 120: 52-58.
36. Chiolero A, Faeh D, Paccaud F, Cornuz J. Consequences of smoking for body weight, body fat distribution and insulin resistance. Am J Clin Nutr 2008; 87: 801-809.
37. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 ESH-ESC practice guidelines for the MAnagement of arterial hypertension: ESH-ESC Task Force on the MAnagement of arterial hypertension. J Hypertens 2007; 25: 1751-1762.
38. Todd Cade W. Left ventricular dysfunction in huMAn immunodeficiency virus infection. J Cardiometab Syndr 2008; 3: 83-87.
39. Tokudome T, Horio T, Yoshihara F, Suga S, Kawano Y, Kohno M et al. Direct effects of high glucose and insulin on protein synthesis in cultured cardiac myocytes and DNA and collagen synthesis in cardiac fibroblasts. Metabolism 2004; 53: 710-715.